Comparative Pharmacology
Head-to-head clinical analysis: TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE versus XIFYRM.
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
500 mg orally twice daily with food.
None Documented
None Documented
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category D/X
Category C
Antibiotic
Antibiotic